Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 4/20 | 0.80 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.80 |
| ▸ | CCR1 | P32246 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butoxylate SCHEMBL241324 | 0.99 | KCNA3 (0.82) | KCNA3OPRM1CCR1GAAOPRD1 | |
| Butoxylate SCHEMBL23852174 | 0.99 | KCNA3 (0.82) | KCNA3OPRM1CCR1GAAOPRD1 | |
| Butoxylate SCHEMBL8976430 | 0.98 | KCNA3 (0.80) | KCNA3OPRM1CCR1GAAOPRD1 | |
| Butoxylate SCHEMBL21708440 | 0.98 | KCNA3 (0.80) | KCNA3OPRM1CCR1GAAOPRD1 | |
| Butoxylate SCHEMBL3940424 | 0.97 | KCNA3 (0.79) | KCNA3OPRM1CCR1GAAOPRD1 | |
| Butoxylate SCHEMBL3791589 | 0.95 | KCNA3 (0.75) | KCNA3OPRM1CCR1GAAOPRD1 | |
| Butoxylate SCHEMBL6257331 | 0.94 | KCNA3 (0.74) | KCNA3OPRM1CCR1GAAOPRD1 | |
| Butoxylate SCHEMBL8421013 | 0.94 | KCNA3 (0.74) | KCNA3OPRM1CCR1GAAOPRD1 | |
| Butoxylate SCHEMBL18249372 | 0.94 | KCNA3 (0.74) | KCNA3OPRM1CCR1GAA | |
| Butoxylate SCHEMBL15862494 | 0.94 | KCNA3 (0.74) | KCNA3OPRM1CCR1GAAOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022052278-A1 | ULTRAVIOLET CROSS-LINKED POLYPHOSPHAZENE, PREPARATION METHOD THEREFOR, USE THEREOF, TEMPERATURE MEASUREMENT OPTICAL FIBER HAVING COMPOSITE COATING USED IN LOW TEMPERATURE AND PREPARATION METHOD THEREFOR | 东部超导科技（苏州）有限公司 | 2022-03-17 | — | — | WO | claimed |
| WO-2022052278-A1 | ULTRAVIOLET CROSS-LINKED POLYPHOSPHAZENE, PREPARATION METHOD THEREFOR, USE THEREOF, TEMPERATURE MEASUREMENT OPTICAL FIBER HAVING COMPOSITE COATING USED IN LOW TEMPERATURE AND PREPARATION METHOD THEREFOR | 东部超导科技（苏州）有限公司 | 2022-03-17 | — | — | WO | disclosed |
| US-7968550-B2 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7223788-B2 | therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | KCNA3 820/4885OPRM1 404/4885CCR1 2647/4885 |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | CYP11B2, CYP11B1, NQO1 | KCNA3 891/4885OPRM1 450/4885CCR1 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.